Sales

Sales

Company News: InVentiv Health

InVentiv Health acquired ParagonRx, a consulting company specializing in pharma risk management and optimizing medication use. The acquisition is aimed at bolstering inVentiv's Risk Evaluation and Mitigation Strategy offering . In the past year, the network noted, more than a quarter of all new drug approvals in the US included an FDA-approved REMS program.

Sales

Watchdogs want FDA number in ads

Arguing that most Americans don't know about the FDA's adverse events reporting program, Consumers Union said DTC ads should include a toll-free number that patients can use to report side effects to the FDA.

Sales

GlaxoSmithKline faces more Avandia fallout

GlaxoSmithKline is in Congressional crosshairs over its marketing of Avandia, and investors arent happy either.

Sales

AMA hooks up online with Sermo

The American Medical Association announced it is partnering with Sermo, the online community for physicians.

Sales

LLNS rebrands as LyonHeart

Lyons Lavey Nickel Swift is rebranding as “LyonHeart” under its proprietary creative-strategic process dubbed “Disruption.”

Sales

Nexavar also seen as liver cancer breakthrough

Onyx and Bayers kidney cancer drug Nexavar (sorafenib) was also found to extend the lives of liver cancer patients in a clinical trial by almost three months, or 44%, doctors said.

Sales

InVentiv buys brand ID shop Addison Whitney

InVentiv Health has acquired brand identity shop Addison Whitney.

Sales

Panel to review Sanofi-Aventis’ Ketek

The FDA will convene a joint panel of outside experts to examine the risks and benefits of Sanofi-Aventis’ antibiotic Ketek (telithromycin).

Sales

Panel to review Sanofi-Aventis’ Ketek

The FDA will convene a joint panel of outside experts to examine the risks and benefits of Sanofi-Aventis’ antibiotic Ketek (telithromycin).

Sales

AHA forbids Pfizer from presenting torcetrapib results

Pfizer won’t be allowed to present new data on its closely watched developmental drug torcetrapib at the annual American Heart Association (AHA) meeting this week.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.